Vancouver, British Columbia –TheNewswire -7 April, 2025–MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6),(the “Company” or “MindBio”),is a clinical stage biopharmaceutical company targeting depressive illnesses currently dosing in multiple Phase 2B clinical trials.
The Company today has issued 3,428,571 common share purchase warrants (the “Warrants”), to Haywood Securities in connection with the completion of strategic investment and advisory services to the Company. The Warrants are exercisable until 4:30pm on 6 April 2026, and are exercisable at a price per share of CAD$0.05, (the “Exercise Price”).
We invite you to join us in support of creating a brighter future for mental health.
For further information, please contact:
Justin Hanka, Chief Executive Officer
justin@mindbiotherapeutics.com
pr@hlthcommunications.com
About MindBio Therapeutics
MindBio is a leading biotech/biopharma company focused on creating novel and emerging treatments for mental health conditions and is conducting world first take-home Microdosing (MB22001) human clinical trials. MB22001 is MindBio’s lead candidate drug, a proprietary titratable form of Lysergic Acid Diethylamide (LSD) designed for take-home microdosing. MindBio is a leader in microdosing of psychedelic medicines and is advancing its drug and technology protocols through clinical trials. MindBio has developed a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development and digital therapeutics, has completed Phase 1 clinical trials in 80 healthy participants and has completed a Phase 2a clinical trial in patients with Major Depressive Disorder, both trials with positive top line data reported. Currently underway are two Phase 2B trials, one in cancer patients experiencing existential distress and another in patients with Major Depressive Disorder. The Company is also approved for multiple Phase 1/Phase 2B trials in women’s health. MindBio invests in research that forms the basis for developing novel and clinically proven treatments including digital technologies and interventions to treat debilitating health conditions such as depression, anxiety and other related mental health conditions.